直击业绩会 | 腾盛博药2024年净亏损扩大190.66% 董事会主席:讨论商业化还为期尚早

每日经济新闻
01 Apr

每经记者 林姿辰 每经编辑 陈俊杰无营业收入,净亏损5.08亿元,同比扩大190.66%。这是新冠中和抗体药物停产后,腾盛博药首个完整年度的业绩情况。目前,公司还没有其他商业化产品,市值从历史最高的360多亿港元,下跌至不足18亿港元。缩减同样发生在研发管线上。2022年,腾盛博药已建立了一系列10个创新候选产品的管线,但在2024年年报中,公司只披露了7个主要候选产品的开发进展。“在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10